Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • XRX-225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News
Apr 30, 2020 9:02am EDT

XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials

Apr 30, 2020 8:30am EDT

XORTX Provides Overview and Update of Key Activities

Mar 26, 2020 7:00am EDT

XORTX Announces New Clinical Advisory Board Member

Mar 16, 2020 11:00am EDT

XORTX Launches XRx-101 Following the Filing of a Provisional Patent to Potentially Treat Respiratory and Kidney Disease Injury Due to Coronavirus Infection

Mar 16, 2020 7:00am EDT

XORTX Launches XRx-101, A New Program to Treat Coronavirus COVID-19 Infection

Sep 19, 2019 9:00pm EDT

XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)

Sep 04, 2019 7:00am EDT

XORTX Highlights New Research on Polycystic Kidney Disease Awareness Day

Jul 30, 2019 7:00am EDT

XORTX Announces Virtual Investor Conference Live Webcast

Jul 18, 2019 8:38pm EDT

XORTX Reports Annual & Special Meeting Results

Jul 15, 2019 7:00am EDT

XORTX Shares Nature Nephrology Review

  • arrow_back
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • arrow_forward
rss_feed News RSS
©2023 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap